FILTAR POR REGIÃO
ACESSO INTEGRAL A CONTEÚDOS
Efetue login ou registe-se
info destaques
-
CAR T-Cell Immunotherapy Induces Complete Remissions in Patients with Refractory DLBCL
ESMO - European Society of Cancer Immunology and Immunotherapy
-
FDA Approves Pembrolizumab for Patients with Recurrent or Metastatic HNSCC with Disease Progression on or After Platinum-Containing Chemotherapy
ESMO - European Society of Cancer Immunology and Immunotherapy
-
Personalised Cancer Vaccines
ESMO - European Society of Cancer Immunology and Immunotherapy
-
In Search of Biomarkers in Onco-Immunology
ESMO - European Society of Cancer Immunology and Immunotherapy
-
FDA Approves Pembrolizumab for First-Line Treatment of Metastatic NSCLC
ESMO - European Society of Cancer Immunology and Immunotherapy
-
EMA Recommends to Extend Indications for Pembrolizumab
ESMO - European Society of Cancer Immunology and Immunotherapy
-
EMA Adopts a New Indication for Nivolumab
ESMO - European Society of Cancer Immunology and Immunotherapy
-
FDA Approves Nivolumab for SCCHN
ESMO - European Society of Cancer Immunology and Immunotherapy
-
Durvalumab in Heavily Pretreated EGFR/ALK Wildtype Advanced NSCLC
ESMO - European Society of Cancer Immunology and Immunotherapy
-
FDA Approves Atezolizumab for Metastatic NSCLC
ESMO - European Society of Cancer Immunology and Immunotherapy
-
Atezolizumab in Patients With Locally Advanced and Metastatic Urothelial Carcinoma
ESMO - European Society of Cancer Immunology and Immunotherapy
-
KEYNOTE-045 Study Meets Primary Endpoint and Stops Early
ESMO - European Society of Cancer Immunology and Immunotherapy
-
Acquired Resistance to PD-1 Blockade in Melanoma
ESMO - European Society of Cancer Immunology and Immunotherapy
-
Evolving Field of CAR-T-Cell Therapy
ESMO - European Society of Cancer Immunology and Immunotherapy
-
NICE Issues Evidence Based Recommendations on Nivolumab for Previously Treated Advanced RCC
ESMO - European Society of Cancer Immunology and Immunotherapy